EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prolonged headache with vaccine- and dose-specific headache pattern associated with vaccine against SARS-CoV-2 in patients with migraine

Ai Seon Kuan iD, Shih-Pin Chen iD, Yen-Feng Wang, Shuu-Jiun Wang iD

Cephalalgia · 2023

DOI: 10.1177/03331024231208110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cephalalgia, 2023. Verfasst von Ai Seon Kuan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Migraine Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Yang Ming Chiao Tung University, Taipei Veterans General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To examine SARS-CoV-2 vaccine-related headache characteristics and risk factors in migraine patients.

Methods

This retrospective cohort study included 732 migraine patients who had AstraZeneca Vaxzevria, Pfizer-BioNTech Comirnaty, or Moderna Spikevax vaccines. Participants provided information through questionnaires and headache diaries. Headache frequency before and after vaccination and factors associated with headache risk were examined.

Results

Approximately a third of patients reported increased headache the day after having primary and booster doses, with mean increase ± SD of 1.9 ± 1.2 and 1.8 ± 1.1 days/week, respectively. Proportions of migraine patients with headache (after vaccination vs. before vaccination) increased after having primary-dose Vaxzevria (35.3% vs. 22.8%, p < 0.001) but not Spikevax (23.8% vs. 26.7%, p = 0.700) or Comirnaty (33.2% vs. 25.8%, p = 0.058). Headache proportion increased after having all three boosters (Vaxzevria 27.1% vs. 17.9% p = 0.003; Comirnaty 34.1% vs. 24.5% p = 0.009; Spikevax 35.2% vs. 24.8% p = 0.031). For primary dose with Vaxzevria and Comirnaty, headache risk increased on the vaccination day, peaked on the day after vaccination, and subsided within a week, while for Spikevax headache risk rose gradually after vaccination, peaked on the seventh post-vaccination day and subsided subsequently. For booster dose, headache risk generally increased on the vaccination day, peaked on the day after vaccination, and subsided gradually with fluctuating pattern within a month. Our study also showed that headache increased on the day before primary dose but not booster dose vaccination and it may be attributable to stress associated with having to undertake new vaccines. Multivariable analyses showed that depression was associated with headache.

Conclusion

Prolonged headache with vaccine- and dose-specific headache pattern was found. Patients with higher risks of vaccine-related headache must be informed of the potential worsening headache.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesMigraine DisordersHumans2019-nCoV Vaccine mRNA-1273BNT162 VaccineChAdOx1 nCoV-19HeadacheRetrospective StudiesSARS-CoV-2Vaccines

Stichwörter der Autor:innen

AstraZeneca VaxzevriaCOVID-19Moderna SpikevaxPfizer-BioNTech Comirnatyadverse event

Substanzen

2019-nCoV Vaccine mRNA-1273BNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesVaccines

Autor:innen und Institutionen

  • Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Institute of Public Health, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Division of Translational Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.

ORCID-Profile: Ai Seon Kuan, Shih-Pin Chen, Shuu-Jiun Wang

Förderung

  • Ministry of Science and Technology, Taiwan
  • National Yang Ming Chiao Tung University
  • Taipei Veterans General Hospital

Zitieren

APA

Kuan, A. S., Chen, S. P., Wang, Y. F., & Wang, S. J. (2023). Prolonged headache with vaccine- and dose-specific headache pattern associated with vaccine against SARS-CoV-2 in patients with migraine. Cephalalgia. https://doi.org/10.1177/03331024231208110

Vancouver

Kuan AS, Chen SP, Wang YF, Wang SJ. Prolonged headache with vaccine- and dose-specific headache pattern associated with vaccine against SARS-CoV-2 in patients with migraine. Cephalalgia. 2023. doi:10.1177/03331024231208110

BibTeX
@article{Kuan2023,
  author = {Kuan, Ai Seon and Chen, Shih-Pin and Wang, Yen-Feng and Wang, Shuu-Jiun},
  title = {Prolonged headache with vaccine- and dose-specific headache pattern associated with vaccine against SARS-CoV-2 in patients with migraine},
  journal = {Cephalalgia},
  year = {2023},
  doi = {10.1177/03331024231208110}
}
Kostenlos starten →